FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891854881> ?p ?o ?g. }

• W2891854881 abstract "Abstract Background Neo-adjuvant chemotherapy (NAC) became to be a standard therapeutic strategy for advanced esophageal squamous cell carcinoma in Japan. However the multidrug combination chemotherapy with 5-FU, cisplatin (FP) and docetaxel (DFP) has been well known more effective than FP, biomarker predict efficacy of NAC is not known yet. We have reported that expression of HER2 and EGFR had correlated to the response of neoadjuvant chemotherapy and prognosis. Therefore we started to evaluate them in all cases using biopsy tissue samples from 2012. Methods The tissues were collected from 122 patients with esophageal squamous cell carcinoma before NAC with DFP from August 2012 to August 2017, and expression of HER2 and EGFR were measured with Immunohistochemistry. HER2 positive were 2 + and 3 + expression in immunostaining. The number of the patients were 20 cases in stageII, 91 cases in stageIII, and 11 cases in stageIV. These results were compared with response to NAC and outcome of the patients. Results There were no differences in patient background factors such as sex, age, location and stage.One hundred nineteen of 122 cases (97.5%) were positive for EGFR and HER2 positive cases were 12 cases (9.8%). Expression patterns of EGFR and HER2 were examined, EGFR positive-HER2 negative cases were the most common pattern, and 107 cases (87.7%), both positive were 12 cases (9.8%), and both negative were 3 cases (2.4%), EGFR negative-HER2 positive were not observed. The response rates of chemotherapy was 46.2% in the EGFR positive cases, it was 42.9% in EGFR positive-HER2 negative cases. It was 75% in HER2 and EGFR positive cases, and it was significantly higher than the other pattern (P = 0.034). HER2 expression was suggested to be a biomarker of NAC with DFP especially in stage III. Conclusion HER2 and EGFR expression was shown to be a predictor of NAC response. The patients with both negative pattern showed poorer response. The expression pattern of HER2 and EGFR can be useful biomarker of NAC response with DFP. Disclosure All authors have declared no conflicts of interest." @default.
• W2891854881 created "2018-09-27" @default.
• W2891854881 creator A5020318740 @default.
• W2891854881 creator A5039391806 @default.
• W2891854881 creator A5048840982 @default.
• W2891854881 creator A5076042448 @default.
• W2891854881 creator A5082896620 @default.
• W2891854881 date "2018-09-01" @default.
• W2891854881 modified "2023-09-27" @default.
• W2891854881 title "RA10.01: TREATMENT STRATEGY OF ESOPHAGEAL CANCER FROM THE EXPRESSION OF HER2 AND EGFR" @default.
• W2891854881 doi "https://doi.org/10.1093/dote/doy089.ra10.01" @default.
• W2891854881 hasPublicationYear "2018" @default.
• W2891854881 type Work @default.
• W2891854881 sameAs 2891854881 @default.
• W2891854881 citedByCount "0" @default.
• W2891854881 crossrefType "journal-article" @default.
• W2891854881 hasAuthorship W2891854881A5020318740 @default.
• W2891854881 hasAuthorship W2891854881A5039391806 @default.
• W2891854881 hasAuthorship W2891854881A5048840982 @default.
• W2891854881 hasAuthorship W2891854881A5076042448 @default.
• W2891854881 hasAuthorship W2891854881A5082896620 @default.
• W2891854881 hasConcept C121608353 @default.
• W2891854881 hasConcept C126322002 @default.
• W2891854881 hasConcept C143998085 @default.
• W2891854881 hasConcept C2779742542 @default.
• W2891854881 hasConcept C502942594 @default.
• W2891854881 hasConcept C71924100 @default.
• W2891854881 hasConceptScore W2891854881C121608353 @default.
• W2891854881 hasConceptScore W2891854881C126322002 @default.
• W2891854881 hasConceptScore W2891854881C143998085 @default.
• W2891854881 hasConceptScore W2891854881C2779742542 @default.
• W2891854881 hasConceptScore W2891854881C502942594 @default.
• W2891854881 hasConceptScore W2891854881C71924100 @default.
• W2891854881 hasLocation W28918548811 @default.
• W2891854881 hasOpenAccess W2891854881 @default.
• W2891854881 hasPrimaryLocation W28918548811 @default.
• W2891854881 hasRelatedWork W1485253907 @default.
• W2891854881 hasRelatedWork W1566993644 @default.
• W2891854881 hasRelatedWork W1582999690 @default.
• W2891854881 hasRelatedWork W1963862380 @default.
• W2891854881 hasRelatedWork W1966692990 @default.
• W2891854881 hasRelatedWork W2008914408 @default.
• W2891854881 hasRelatedWork W2083527129 @default.
• W2891854881 hasRelatedWork W2240202605 @default.
• W2891854881 hasRelatedWork W2243547424 @default.
• W2891854881 hasRelatedWork W2269599570 @default.
• W2891854881 hasRelatedWork W2273625236 @default.
• W2891854881 hasRelatedWork W2319587259 @default.
• W2891854881 hasRelatedWork W2593284394 @default.
• W2891854881 hasRelatedWork W2761196942 @default.
• W2891854881 hasRelatedWork W2900594595 @default.
• W2891854881 hasRelatedWork W3029937147 @default.
• W2891854881 hasRelatedWork W3032828532 @default.
• W2891854881 hasRelatedWork W3091006754 @default.
• W2891854881 hasRelatedWork W3127763729 @default.
• W2891854881 hasRelatedWork W1047953701 @default.
• W2891854881 isParatext "false" @default.
• W2891854881 isRetracted "false" @default.
• W2891854881 magId "2891854881" @default.
• W2891854881 workType "article" @default.